FDA chief to depart after Trump signed off on ousting him

FDA Chief to Depart After Trump Signed Off on Ousting Him

FDA chief to depart after Trump – President Donald Trump has formally approved the removal of Food and Drug Administration (FDA) Commissioner Marty Makary, according to three individuals with insider knowledge of the decision. This marks the end of Makary’s tenure in the administration, which has been characterized by internal strife and external criticism. The departure follows a series of mounting pressures from within the executive branch, as well as from outside groups such as pharmaceutical companies and anti-abortion advocates.

Internal and External Pressures Fuel Resignation

Makary’s leadership at the FDA has been a focal point of contention, particularly due to his resistance to approving flavored e-cigarettes. This issue sparked direct confrontations with Trump, who has repeatedly emphasized the need to regulate vaping products to protect young consumers. The commissioner’s stance, while aligned with public health concerns, clashed with the administration’s broader priorities, leading to persistent pressure from within. White House officials and senior health department staff grew increasingly frustrated with the FDA’s internal conflicts and policy indecision.

Outside the administration, pharmaceutical industry leaders and anti-abortion groups have criticized Makary’s management style. His decision to delay approvals for certain drugs, as well as his approach to tobacco regulation, has drawn backlash. These groups view his leadership as a barrier to swift regulatory actions that align with their interests. The cumulative effect of these pressures has created an environment where Makary’s position became untenable, despite his efforts to maintain support.

Leadership Changes and New Vacancies

Trump’s decision to replace Makary has led to the appointment of Kyle Diamantas, a deputy commissioner overseeing the agency’s food programs, as acting head. Diamantas’s move was confirmed in a Truth Social post by the president, who expressed satisfaction with the change. This transition adds to the list of high-level vacancies within the U.S. Department of Health and Human Services (HHS), which already lacks a permanent leader for the Centers for Disease Control and Prevention (CDC) and the surgeon general position.

Senate confirmation for the permanent FDA commissioner will be required, creating a bureaucratic hurdle for the administration. Health and Human Services Secretary Robert F. Kennedy Jr. highlighted the urgency of the search for a new commissioner, stating in a recent X post: “The search for a new Commissioner is already underway, and we will move forward with urgency.” This announcement underscores the political importance of the FDA chief role, especially as the midterms approach.

The departure of Makary also coincides with a significant development: his planned testimony before the Senate Appropriations Committee. The timing of his resignation, just days before this appearance, has raised questions about the administration’s strategy to manage public perception. Some insiders suggest that the move was intended to preempt potential criticism of the FDA’s budget proposals, while others argue it reflects a deeper dissatisfaction with his leadership.

Reasons for the Resignation

According to a source close to Makary’s exit, the primary cause of his resignation was a disagreement over the flavored e-cigarette policy. “He doesn’t want to approve youth-appealing flavors, but has been forced to by the powers that be,” the person said. This conflict reached a boiling point when Trump directly confronted Makary about his decisions, prompting the FDA to reverse its stance on fruit-flavored e-cigarettes last week.

Makary’s tenure has also been marked by frequent changes in the agency’s upper management. His leadership faced scrutiny from within the HHS, where internal factions disagreed on the direction of regulatory policies. This churn has affected the FDA’s ability to maintain consistent strategies, further complicating its role in shaping public health regulations. The commissioner’s efforts to streamline decision-making on drugs, devices, and vaccines, which he pledged upon his March 2025 confirmation, have been overshadowed by these internal challenges.

Political Strategy and Implications

While some Trump aides initially hesitated to remove Makary, fearing a political misstep, others viewed his departure as inevitable. The administration’s “Make America Healthy Again” coalition had grown restless with the FDA’s perceived indecision, and the decision to replace Makary was seen as a way to consolidate control over key health policy areas. This move also aims to improve relations with critical constituencies, including the anti-abortion movement and the pharmaceutical industry, ahead of the November elections.

The push for Makary’s removal has accelerated in recent weeks, driven by a coalition of White House and HHS officials who have grown disillusioned with the FDA’s internal dynamics. The agency’s reputation for chaos and policy confusion has fueled the desire for a leadership overhaul. By appointing Diamantas, Trump is signaling a shift toward more streamlined and politically aligned decision-making, which could have long-term implications for the FDA’s regulatory approach.

Another key moment in Makary’s departure occurred when Susan B. Anthony Pro-Life America’s President, Marjorie Dannenfelser, met with White House officials to advocate for reversing regulations that allow e-cigarettes to be sold in flavored varieties. This interaction highlighted the growing influence of anti-abortion groups within the administration and their role in shaping FDA policies. The administration’s focus on aligning with these groups reflects broader priorities, including the regulation of tobacco and vaping products as part of a larger agenda to curb nicotine use among youth.

Despite his efforts to retain Trump’s favor, Makary’s resignation came as a surprise to many of his allies. Earlier in the week, he had expressed confidence in the president’s support, according to associates. However, the sudden approval of his removal by Trump suggests that the administration’s priorities had shifted, and that Makary’s resistance to certain policies was seen as a major obstacle.

The FDA’s restructuring extends beyond Makary’s departure, with officials considering changes to the agency’s senior staff. This effort to reorganize leadership is part of a broader strategy to ensure alignment with Trump’s vision for health policy. The new acting commissioner, Diamantas, is expected to implement these changes swiftly, potentially streamlining the FDA’s operations and reducing internal friction.

Makary’s resignation has sparked discussions about the future of the FDA and its role in regulating public health. While his tenure was marked by controversy, it also highlighted the challenges of balancing scientific integrity with political influence. As the administration moves forward, the focus will be on selecting a new commissioner who can navigate these complex dynamics and advance the priorities of the current administration.